DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION

DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION

The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KIYONO, Yuji, YAMANO, Hitoshi, SHIMIZU, Yoshitaka, IJIRO, Tomoyuki
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator KIYONO, Yuji
YAMANO, Hitoshi
SHIMIZU, Yoshitaka
IJIRO, Tomoyuki
description The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3315128B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3315128B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3315128B13</originalsourceid><addsrcrecordid>eNqNyz0OwjAMQOEsDAi4gy_AUCokVjdxWkshrpzws1UVChOCSuX-goEDML3le0tzcpI4tqDU8pEiiAeVM2ZWChzBiwJmvDICpiSWMZODC-cOUs9RLCk1FAIqOGopkn5XiWuzuI-PuWx-XRnwlG23LdNrKPM03sqzvAfq67raV7tDU9V_kA8TVjAt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION</title><source>esp@cenet</source><creator>KIYONO, Yuji ; YAMANO, Hitoshi ; SHIMIZU, Yoshitaka ; IJIRO, Tomoyuki</creator><creatorcontrib>KIYONO, Yuji ; YAMANO, Hitoshi ; SHIMIZU, Yoshitaka ; IJIRO, Tomoyuki</creatorcontrib><description>The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210519&amp;DB=EPODOC&amp;CC=EP&amp;NR=3315128B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210519&amp;DB=EPODOC&amp;CC=EP&amp;NR=3315128B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KIYONO, Yuji</creatorcontrib><creatorcontrib>YAMANO, Hitoshi</creatorcontrib><creatorcontrib>SHIMIZU, Yoshitaka</creatorcontrib><creatorcontrib>IJIRO, Tomoyuki</creatorcontrib><title>DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION</title><description>The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyz0OwjAMQOEsDAi4gy_AUCokVjdxWkshrpzws1UVChOCSuX-goEDML3le0tzcpI4tqDU8pEiiAeVM2ZWChzBiwJmvDICpiSWMZODC-cOUs9RLCk1FAIqOGopkn5XiWuzuI-PuWx-XRnwlG23LdNrKPM03sqzvAfq67raV7tDU9V_kA8TVjAt</recordid><startdate>20210519</startdate><enddate>20210519</enddate><creator>KIYONO, Yuji</creator><creator>YAMANO, Hitoshi</creator><creator>SHIMIZU, Yoshitaka</creator><creator>IJIRO, Tomoyuki</creator><scope>EVB</scope></search><sort><creationdate>20210519</creationdate><title>DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION</title><author>KIYONO, Yuji ; YAMANO, Hitoshi ; SHIMIZU, Yoshitaka ; IJIRO, Tomoyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3315128B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KIYONO, Yuji</creatorcontrib><creatorcontrib>YAMANO, Hitoshi</creatorcontrib><creatorcontrib>SHIMIZU, Yoshitaka</creatorcontrib><creatorcontrib>IJIRO, Tomoyuki</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KIYONO, Yuji</au><au>YAMANO, Hitoshi</au><au>SHIMIZU, Yoshitaka</au><au>IJIRO, Tomoyuki</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION</title><date>2021-05-19</date><risdate>2021</risdate><abstract>The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP3315128B1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A55%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KIYONO,%20Yuji&rft.date=2021-05-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3315128B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true